Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。